CIK 0001321834
- Non-accelerated filer
- Smaller reporting company
Q/C TECHNOLOGIES, INC.
Sign in to watch- Ticker
- QCLS
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 856-848-8698
- Business address
- 1185 AVENUE OF THE AMERICAS, SUITE 249, NEW YORK, NY, 10036
- Former names
- Q/C TECHNOLOGIES, INC., TNF Pharmaceuticals, Inc., MyMD Pharmaceuticals, Inc., Akers Biosciences, Inc., Akers Biosciences Inc
- 4 Derivatives Options or other derivatives
- 4 Grant or award President, Chief Med. Officer acquired 96,475 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Shares withheld for taxes Director gave up 14,694 shares (to pay taxes)
- 4 Shares withheld for taxes Director gave up 38,325 shares (to pay taxes)
- 4 Shares withheld for taxes Director gave up 38,325 shares (to pay taxes)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale 10% owner sold 638 shares at $2.81 ($1,793)
- 4 Open-market sale 10% owner sold 28,300 shares at an average $2.81 ($79,576)
- 4 Open-market buy 10% owner bought 184,578 shares at an average $3.01 ($555,550)
- 3 Insider Initial Statement of Ownership
- 4 Option exercise Executive Chairman acquired 5,201 shares (option exercise)
Page 4 of 7 · 132 filings